Understanding the science behind Nirmatrelvir/Ritonavir Pfizer | Rwanda

Nirmatrelvir/Ritonavir Pfizer

Home

About

Efficacy

Trial Design

Safety

Important Safety Information

Safety & Tolerability

Dosing

Dosing Information

Dose Adjustments

Drug Interactions

Medical Information

Visit the Pfizer Medical Information Africa Website for Healthcare Professionals

Submit a medical question to Pfizer

To report an adverse event, please contact [email protected]

Mechanism of Action

Understanding the science behind Nirmatrelvir/Ritonavir Pfizer

How Nirmatrelvir/Ritonavir Pfizer works

1. Proteolysis

In the SARS-CoV-2 life cycle, proteolysis involves the cleavage of viral polyprotein chains by proteases to release the nonstructural proteins that are essential for viral replication.³

2. M^pro

Due to its essential function in viral replication, mutations that occur to M^pro can be lethal to the virus.⁴

3. PF-07321332

Inhibition of M^pro by PF-07321332 prevents proteolysis, helping to halt the viral replication cycle.^1,3

The role of ritonavir¹

Ritonavir is administered with PF-07321332 as a pharmacokinetic (PK) enhancer, resulting in higher systemic concentrations of
PF-07321332 and helping to support twice-daily dosing.^1,2

Ritonavir has an established safety profile and is used in combination with other antivirals as a PK enhancer^1,2,5

EXPLORE MORE

Dosing

Learn about the oral treatment schedule, dose adjustments, and drug interactions.

Dosing information

Dose adjustments

Drug interactions

References: 1. Nirmatrelvir/Ritonavir Pfizer Summary of Product Characteristics. 2. Owen DR, Allerton CMN, Anderson AS, et al. An oral SARS-CoV-2 Mpro inhibitor clinical candidate for the treatment of COVID-19. Science. 2021;374(6575):1586-1593. 3. Senger MR, Evangelista TCS, Dantas RF, et al. COVID-19: molecular targets, drug repurposing and new avenues for drug discovery. Mem Inst Oswaldo Cruz. 2020;115:e200254. 4. Goyal B, Goyal D. Targeting the dimerization of the main protease of coronaviruses: a potential broad-spectrum therapeutic strategy. ACS Comb Sci. 2020;22(6):297-305. 5. NORVIR Summary of Product Characteristics.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua.

To report an adverse event, please contact [email protected]
Click here to Submit a Medical Question.
Terms of Use
Cookies & Privacy Policy
Contact: KENYA OFFICE: Pfizer Laboratories (Pty) Ltd Vienna Court, First Floor West Wing, State House Crescent, State House Road, Nairobi Kenya, PO Box 18244-00500.
Tel: +254(0)5134110.
Pfizer.com

This site is intended only for Rwanda health care professionals. The products discussed in this site may have different product labeling in different countries. The information provided is for educational purposes only.

Disclaimer: The product is not yet licensed by the Board of Health of Rwanda (Rwanda FDA). The product has however obtained prior Board of Health approval for supply to Accord program channels in Rwanda.

You are now leaving Accord Portal to access Pfizer Medical Information Portal

You are now leaving a Pfizer operated website. Links to all outside sites are provided as a resource to our visitors. Pfizer accepts no responsibility for the content of sites that are not owned and operated by Pfizer.